Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05584111 · ClinicalTrials.gov registry record · Phase 1
Oral Administration of STC-15 in Subjects With Advanced Malignancies
A Phase 1 study of Cancer and Advanced Solid Tumor, sponsored by STORM Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT05584111 is a Phase 1 study of Cancer and Advanced Solid Tumor that has completed, run by STORM Therapeutics. The registered enrollment target is 42 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05584111, a Phase 1 study of Cancer and Advanced Solid Tumor, has completed, sponsored by STORM Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies. Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs). The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers.
Conditions Studied
Interventions
- DRUG STC-15
Study Locations (3)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
Arizona
- Honor Health - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05584111
The ClinicalTrials.gov registry entry for NCT05584111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is STORM Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which STC-15 is the first listed.
NCT05584111 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT05584111 about?
NCT05584111 is a clinical study titled "Oral Administration of STC-15 in Subjects With Advanced Malignancies". This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm. The study is designed to systematically assess safety and tolerability, p...
What is the current status of trial NCT05584111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2022-11-15. Estimated completion is 2024-12-22.
What conditions does trial NCT05584111 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumor, Advanced Cancer.
What interventions are being tested in trial NCT05584111?
The interventions under investigation include: STC-15 (DRUG).
Who is sponsoring clinical trial NCT05584111?
This trial is sponsored by STORM Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05584111 being conducted?
This trial has 3 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.